HB910 would establish a Rare Disease Advisory Council within the Hawaii Department of Health to advise the legislature, agencies, and the public on the needs of people living with rare diseases in Hawaii. The council would be tasked with holding public hearings, surveying patient and provider needs, consulting experts, identifying research and policy gaps, improving access to specialists and diagnostics, and recommending changes to Medicaid and private insurance coverage. It would also maintain a public website, meet regularly, and submit annual reports with findings and proposed legislation.
The bill also creates a rare disease advisory council special fund and appropriates $50,000 for each of fiscal years 2025-2026 and 2026-2027 to support the council’s establishment and operations. In addition, it directs the Department of Health and Department of Education to include information about the importance of annual physical examinations for children in their programs and communications. The bill further amends Hawaii’s insurance law to require coverage for medically necessary orthodontic services for individuals with velocardiofacial syndrome and related orofacial anomalies, with no copayment, deductible, or coinsurance for that coverage and with existing benefit limits adjusted for inflation.
In practical terms, the bill would add a new advisory body and special fund to Hawaii law, expand public-health messaging about children’s annual physical exams, and broaden insurance protections for a specific rare genetic condition. It would affect the Department of Health, the Department of Education, insurers, health plans, Medicaid-related policy discussions, rare disease patients and caregivers, and providers involved in genetic, craniofacial, and specialty care. The insurance amendments are targeted to individuals under 26 covered by qualifying plans and would reinforce existing coverage for medically necessary orthodontic treatment tied to these conditions.
The overall sentiment reflected in the bill text is strongly supportive of rare disease patients and families, emphasizing unmet medical needs, delayed diagnoses, health disparities, and the value of coordinated state action. The bill frames the council as a way to improve awareness, access to care, and policy development, and it cites the experience of other states that have created similar councils. Because there are no committee transcripts or votes provided, there is no recorded public debate or vote history in the supplied materials to indicate broader legislative support or opposition.
The main points of potential contention are likely to be the creation and funding of a new state advisory council, the scope of its membership and duties, and the insurance mandate requiring specific coverage without cost sharing. Stakeholders that could have differing views include insurers, health plans, the biopharma industry, Medicaid administrators, and state agencies concerned about administrative burden or costs, versus patients, caregivers, clinicians, researchers, and advocacy groups who would likely support the bill’s expanded attention to rare diseases and coverage protections.
HB910 would amend Hawaii law by adding a new rare disease advisory council within Chapter 321, creating a special fund, and requiring annual reporting to the Legislature. It would also revise existing public-health and education provisions to include information on the importance of annual physical examinations for children, and it would amend the insurance code to require specified orthodontic coverage for velocardiofacial syndrome and related orofacial anomalies, including a prohibition on cost sharing for that coverage. The bill appropriates state general funds and would directly affect the Department of Health, Department of Education, insurers, health plans, Medicaid-related policy review, and rare disease patients and families.
The bill’s tone is generally favorable and advocacy-oriented, with the Legislature finding that rare diseases create substantial diagnostic, treatment, and financial barriers and that a state advisory council could improve awareness and policy responses. The measure is framed as a public-health and health-equity initiative, and its stated purpose is to improve medical intervention and access to care. No committee discussion or vote record was provided, so there is no documented opposition or amendment debate in the supplied materials.
The most likely areas of contention are the creation of a new state council and special fund, the $50,000 annual appropriation, and the insurance mandate for orthodontic services without copayments, deductibles, or coinsurance. Insurers and health plans may be concerned about mandated benefits and administrative costs, while state agencies may weigh the workload of staffing, meetings, and reporting. On the other hand, rare disease patients, caregivers, clinicians, researchers, and advocacy organizations would likely support the bill’s focus on access, diagnostics, and coverage. Because no committee transcripts or votes are included, these are inferred policy tensions rather than recorded objections.